PaxMedica, Inc. stock analysis
PaxMedica, Inc. (PXMD) Stock Price & Analysis
PXMD Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 1.64M
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- MXN 324.49K
- Total Debt (Recent Filing)
- MXN 0
- Price to Earnings (P/E)
- 0.0
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance Sheet
Having no debt enhances financial flexibility and reduces risk, allowing PaxMedica to focus resources on R&D and strategic growth initiatives.
Improved Equity Position
A positive equity position strengthens the balance sheet, providing a buffer against financial instability and supporting future investment opportunities.
Focus On Unmet Needs
Targeting unmet medical needs in neurodevelopmental disorders positions PaxMedica to capture niche markets and potentially secure competitive advantages.
Bears Say
No Revenue Generation
Lack of revenue generation raises concerns about the company's ability to sustain operations and achieve profitability, necessitating strategic changes.
Consistent Net Losses
Ongoing net losses indicate operational inefficiencies and highlight the need for effective cost management and revenue-generating strategies.
Negative Cash Flows
Negative cash flows from operations suggest inefficiencies and potential liquidity issues, which could hinder long-term growth and sustainability.
PaxMedica, Inc. News
PaxMedica announces receives notification to grant patent right in China
PaxMedica (PXMD) has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders,
PXMD FAQ
What is PaxMedica, Inc.’s market cap?
When is PaxMedica, Inc.’s upcoming earnings report date?
How were PaxMedica, Inc.’s earnings last quarter?
Is PaxMedica, Inc. overvalued?
Does PaxMedica, Inc. pay dividends?
What is PaxMedica, Inc.’s EPS estimate?
How many shares outstanding does PaxMedica, Inc. have?
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PaxMedica, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
PaxMedica, Inc.
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Howard J. Weisman
- Employees
- 6
- Website
- www.paxmedica.com
- Address
- 303 South Broadway, Tarrytown, NY, 10591, US
